Cargando…

Oligoprogression in non-small cell lung cancer: a narrative review

BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancers and is the most common non-cutaneous cancer world-wide. In NSCLC, oligometastatic and oligoprogressive disease (OPD) have been recognized as separate entities within the realm of metastatic disease and are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Katarina T., Sakthivel, Gukan, Milano, Michael T., Qiu, Haoming, Singh, Deepinder P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840049/ https://www.ncbi.nlm.nih.gov/pubmed/36647502 http://dx.doi.org/10.21037/jtd-22-536

Ejemplares similares

Oligoprogression in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2021)

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
por: Belluomini, Lorenzo, et al.
Publicado: (2021)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer
por: Kim, Daniel W., et al.
Publicado: (2019)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
por: Lu, Shao-Lun, et al.
Publicado: (2016)

Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
Publicado: (2022)

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer
por: Kagawa, Yusuke, et al.
Publicado: (2020)

Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience
por: Katz, Leah M., et al.
Publicado: (2022)

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
por: Hu, Chunhong, et al.
Publicado: (2022)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Patterns of recurrence after intracranial stereotactic radiosurgery for brain-only metastases from non-small cell lung cancer and the impact of upfront thoracic therapy with synchronous presentation
por: Bergsma, Derek P., et al.
Publicado: (2022)

Radiotherapy for Oligometastatic Lung Cancer
por: Bergsma, Derek P., et al.
Publicado: (2017)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
por: Alomran, Reem, et al.
Publicado: (2021)

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
por: Schoenmaekers, Janna Josephus Anna Oda, et al.
Publicado: (2020)

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019)

Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years
por: Aujla, Khush S., et al.
Publicado: (2019)

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy
por: Lee, Ho Young, et al.
Publicado: (2022)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Stereotactic Radiation for Oligometastatic and Oligoprogressive Stage IV Breast Cancer: A Case-based Review
por: Freedman, Gary M., et al.
Publicado: (2023)

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
por: Schoenhals, Jonathan E., et al.
Publicado: (2021)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
por: Patel, P.H., et al.
Publicado: (2019)

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer
por: Li, Shuai, et al.
Publicado: (2019)

Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies
por: Le, Uyen-Thao, et al.
Publicado: (2023)

A case of repeat oligoprogressive castration‐resistant prostate cancer treated with pulmonary metastasectomy
por: Soma, Takahiko, et al.
Publicado: (2023)

Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
por: Sindhu, Kunal K., et al.
Publicado: (2022)

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review
por: Yan, Bernie, et al.
Publicado: (2023)

Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer
por: Nguyen, Thu-Cuc, et al.
Publicado: (2018)

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review
por: Sundahl, Nora, et al.
Publicado: (2021)

The role of gender in non-small cell lung cancer: a narrative review
por: Baiu, Ioana, et al.
Publicado: (2021)

Bone metastases in non-small cell lung cancer: a narrative review
por: Knapp, Brendan J., et al.
Publicado: (2022)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
por: Rossi, Antonio, et al.
Publicado: (2022)

Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs
por: Damen, Pim J. J., et al.
Publicado: (2023)

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors
por: Ji, Xiaoqin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aq6c1aqnu5a7qs9900e0g8dvj2